| August 16, 2017 |
Webinar: Discovery of Bacterial Effectors in the Human Microbiome and Isolation of a GPCR G2A/GPR132 Agonist - 30 min.
What will be covered?
- The role of GPCRs in regulating host-microbial interactions
- How to identify microbial metabolites that modulate GPCR functions
- A case study on defining host-microbial interaction and therapeutic potential of N-acyl amides, bacterial metabolites that activate GPR132/G2A
|
Login to view
|
Login to view
|
| April 5, 2017 |
Webinar: From Chemistry to Clinic: Discovery of Biased Apelin Receptor Agonists and Action in the Cardiovascular System - 55 min.
What will be covered?
- Role of GPCRs in human cardiovascular system
- Strategies for exploiting orphan GPCRs recently paired with endogenous ligands illustrated by Apelin and Elabela/Toddler
- Identifying biased agonists using pharmacologically-relevant functional cell based assays
- Validating assays and minimizing inter-assay variation
|
Login to view
|
Login to view
|
| March 9, 2017 |
Webinar: Mu Opioid Receptor Splicing and Signaling: Another Dimension of GPCR Function - 55 min.
What will be covered?
- Overview of the mu opioid receptor signaling
- GPCR splicing, using OPRM1 as an example
- Region and cell specific splicing
- Functional consequences of 5’ splicing
- Functional consequences of 3’ splicing
|
Login to view
|
Login to view
|
| February 1, 2017 |
Webinar: Unlocking GPCRs for Oncology - 35 min.
What will be covered?
- Opportunities and challenges for targeting GPCRs in oncology
- Examples of GPCR-targeting investigational therapies for oncology
- Imipridones, selective GPCR-targeting small molecules, that are in preclinical and clinical development for oncology
|
Login to view
|
Login to view
|
| November 9, 2016 |
Webinar: Duplexed Screening of GPCRs to Measure Calcium and β-Arrestin - 60 min.
What will be covered?
- Screening approaches for GPCR drug discovery
- Creating a duplexed assay to monitor calcium and β-arrestin in a single well
- Determine potential bias for various drugs and define potency ranking
|
Login to view
|
Login to view
|
| July 27, 2016 |
Webinar: Understand Safety and Selectivity of Drug Candidates Before Expensive Animal Studies - 60 min.
What will be covered?
- How PathHunter® GPCR Screening and Profiling Services can be used to triage hits, rank order compounds, and develop novel biased ligands
- Tools to understand the mechanism of action of your drugs and their mode of action
- How a case study of clinically approved drugs in our broad range of GPCR assays can be used to predict the selectivity and safety of your drug candidates
|
Login to view
|
Login to view
|
| June 15, 2016 |
Webinar: Make Your Own Cell-Based Assays to Study β-Arrestin Recruitment - 30 min.
What will be covered?
- Overview of β-arrestin biology
- Tools needed to create your own β-arrestin cell lines and assays
- Experimental design and workflows
- Applications of β-arrestin cell-based assays for GPCRs
|
Login to view
|
Login to view
|
| May 19, 2016 |
Webinar: Ready-to-use Potency Assays for Anti-VEGF Drugs Like Bevacizumab, Ranibizumab & Aflibercept - 60 min.
What will be covered?
- Creation of cell-based bioassays for potency and stability testing
- Application, development and validation of assays with drug molecule
- Case studies on Avastin (bevacizumab), Eylea (aflibercept) and Lucentis (ranibizumab)
- Qualified assays for > 30 biosimilars
|
Login to view
|
Login to view
|
| May 12, 2016 |
Webinar: Latest Trends in Ligand Bias and Allosteric Modulators – New Opportunities, Insights and Prospects for Cure - 60 min.
What will be covered?
- Capabilities overview of LeadHunter Discovery Services
- Identifying, characterizing and quantifying novel biased ligands using LeadHunter Services
- Multiple pathways including ß-Arrestin and how biased signaling can influence efficacy in vivo
|
Login to view
|
Login to view
|
| September 24, 2015 |
Ligand Bias Simplified - A Novel Pharmacologic Toolbox - 30 min.
What will be covered
- Capabilities overview of LeadHunter Discovery Services
- How LeadHunter can be used to identify, characterize and quantify novel biased ligands
- Discover how multiple pathways including ß-Arrestin can influence efficacy in vivo
|
Login to view
|
Login to view
|